Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Liver Diseases, Alcohol Use Disorder
Interventions: Stepped alcohol intervention (SAT) to reduce unhealthy alcohol use, Usual Care (UC); Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Posttraumatic Stress Disorder (PTSD)
Interventions: Informed decision making, Placebo session; Behavioral
Lead sponsor: Michael E. DeBakey VA Medical Center; Federal
Eligibility: Not listed
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Participants, Rheumatoid Arthritis (RA) Prevention
Interventions: Hydroxychloroquine, HCQ Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more

Conditions: Hemorrhagic Fever, Ebola
Interventions: Ad26.ZEBOV, MVA-BN-Filo, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 578 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Barrett Esophagus, Esophageal Cancer
Interventions: acetylsalicylic acid, esomeprazole magnesium, placebo; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Atopic Dermatitis
Interventions: Dupilumab, Photo therapy; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation, BRIP1 Gene Mutation, Ovarian Cancer
Interventions: Risk-reducing salpingectomy with delayed oophorectomy, Risk-reducing salpingo-oophorectomy; Procedure
Lead sponsor: University Medical Center Nijmegen; Other
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2040
U.S. locations: 11
States / cities: Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 6 more

Conditions: Quality of Life, Injection Site Reaction, Adverse Drug Event, Systemic Reaction
Interventions: mRNA COVID-19, IIV4, Placebo (saline); Biological · Other
Lead sponsor: Duke University; Other
Eligibility: 5 Years and older
Enrollment: 348 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Baltimore, Maryland • Durham, North Carolina • Cincinnati, Ohio

Conditions: Kidney Stones
Interventions: cephalosporins, Fluoroquinolones, Clindamycin, Ampicillin/Gentamicin; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Manhasset, New York • New Hyde Park, New York

Conditions: Health Behavior
Interventions: Stress Management Control, Adapted MBC2 Program; Behavioral
Lead sponsor: Nancy Schoenberg; Other
Eligibility: 18 Years to 100 Years
Enrollment: 279 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Benham, Kentucky

Conditions: Stress, Covid19, Anxiety
Interventions: Essential Oil Blend, Control Blend; Other
Lead sponsor: Nutraceuticals Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Franklin, Tennessee

Conditions: Primary Immune Deficiency
Interventions: Newnorm; Biological
Lead sponsor: Octapharma; Industry
Eligibility: 2 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 10
States / cities: Irvine, California • Centennial, Colorado • Port Saint Lucie, Florida + 7 more

Conditions: Carcinoma, Squamous Cell of the Head and Neck
Interventions: REOLYSIN, Carboplatin, Paclitaxel, Placebo; Biological · Drug
Lead sponsor: Oncolytics Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 21
States / cities: Birmingham, Alabama • Tucson, Arizona • Burbank, California + 18 more

Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: filgrastim, carboplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, paclitaxel; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2007
U.S. locations: 2
States / cities: New York, New York

Conditions: Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation
Interventions: liposomal daunorubicin citrate, semaxanib, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Peritoneal Neoplasms, Neoplasm Metastasis, Adenocarcinoma, Sarcoma
Interventions: Not listed
Lead sponsor: Edward-Elmhurst Health System; Other
Eligibility: Not listed
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 2
States / cities: Elmhurst, Illinois • Naperville, Illinois

Conditions: Dry Eye
Interventions: Kera Sol Eye Drops; Drug
Lead sponsor: Vance Thompson Vision; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Anxiety Disorders, Depressive Disorder
Interventions: Modular Approach to Therapy for Children (MATCH); Behavioral
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 7 Years to 15 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hyperpigmentation, Photodamaged Skin, Wrinkle, Fine Lines
Interventions: Gentle Cleansing Lotion, Revision Skincare; Other
Lead sponsor: Revision Skincare; Industry
Eligibility: 35 Years to 60 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Solana Beach, California • Greenwood Village, Colorado • Nashville, Tennessee

Conditions: Endometrial Cancer
Interventions: behavioral dietary intervention, exercise intervention, counseling intervention, educational intervention, survey administration; Behavioral · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hypertension
Interventions: Telehealth Follow-up Visits, Surveys, Devices; Behavioral · Device
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Prostate Cancer
Interventions: filgrastim, mitoxantrone hydrochloride; Biological · Drug
Lead sponsor: Hope Cancer Institute, Inc.; Industry
Eligibility: Male only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 2
States / cities: Kansas City, Kansas

Conditions: Rosacea
Interventions: CLS001 (Omiganan), Vehicle; Drug
Lead sponsor: Maruho Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 463 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 13
States / cities: Fremont, California • Miami, Florida • Miramar, Florida + 10 more

Conditions: Scabies
Interventions: Moxidectin Oral Product, Placebo; Drug
Lead sponsor: Medicines Development for Global Health; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Miami, Florida • Tampa, Florida

Search by objective public record fields.

Coronavirus Disease 2019 (Covid-19) Impact on Alcohol-related Liver Disease Patient Outcomes, Care and Alcohol Use

Increasing Engagement in PTSD Treatment Through Patient Education and Patient Choice

Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis

Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus

IL-4 and Insulin Resistance for Treatment of Patients With Atopic Dermatitis

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

Simultaneous mRNA COVID-19 and IIV4 Vaccination Study

Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy

Make Better Choices 2 for Rural Appalachians

The Effect of Aromatherapy on COVID-19-induced Anxiety

Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer

Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy

HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis - Data Registry

Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK

Testing Psychosocial Treatment Planning Methods for Youth Anxiety and Depression

A Multi-Center, Open-label Study Evaluate the Efficacy and Tolerability of a Dual Skincare Regimen Treatment for Facial Hyperpigmentation and Photodamaged Skin in Patients Exposed to Extrinsic Factors of Aging

Exercise and Healthy Diet or Standard Care in Patients in Remission From Stage I or Stage II Endometrial Cancer

Using Bluetooth Home Blood Pressure Monitors With Pharmacist Interventions

Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

Efficacy and Safety Study of Moxidectin in Adults With Scabies